These observations are further validated in four ex vivo explants from HNSCC patients in which combined treatment of cisplatin and NCT-501, a theophylline-based inhibitor of ALDH1A1, results in a significant decrease in proliferating cells as compared with monotherapy (16). Here, ALDH1A1 is linked to head and neck squamous cell carcinoma.